指南与共识心胸血管麻醉

欧洲心胸麻醉学会国际共识:纤维蛋白原与纤维蛋白原浓缩物在心脏手术中的作用

The role of fibrinogen and fibrinogen concentrate in cardiac surgery: an international consensus statement from the Haemostasis and Transfusion Scientific Subcommittee of the European Association of Cardiothoracic Anaesthesiology.
指南 / 共识 · Anaesthesia · 2019-09-17

该国际共识由欧洲心胸麻醉学会止血与输血科学小组制定,针对心脏手术中纤维蛋白原浓缩物疗效与安全性证据有限、研究样本小且异质性大的现状,建议在体外循环脱机前后高危出血患者中用粘弹性床旁检测评估纤维蛋白原活性,不推荐无限制使用Clauss法,并指出对微血管出血可给予纤维蛋白原浓缩物但无需追求超常水平。

要点

  • 高危出血患者体外循环脱机前后用粘弹性床旁检测评估纤维蛋白原活性是合理策略。
  • Clauss法因周转时间长、批间变异大及受肝素和纤维蛋白降解产物干扰,不再推荐无限制使用。
  • 微血管出血时可给予纤维蛋白原浓缩物维持生理水平,但现有证据不支持追求超常水平。

核心结论

  • 心脏手术中纤维蛋白原浓缩物的疗效与安全性证据有限,需大规模前瞻性多中心研究明确最佳监测工具、输血触发点及目标水平。

研究设计与样本

  • 欧洲心胸麻醉学会止血与输血科学小组制定的国际共识声明。

主要发现

  • 现有研究受样本量小、患者人群异质性大、给药时机及输血触发与目标水平定义不一所限。
  • 粘弹性床旁检测在体外循环脱机前后评估纤维蛋白原活性对高危出血患者是合理策略。
  • Clauss法因周转时间长、批间变异大及受高肝素水平和纤维蛋白降解产物干扰,不再推荐无限制使用。
  • 微血管出血时给予纤维蛋白原浓缩物维持生理纤维蛋白原活性似有指征,但证据不支持追求超常水平。
  • 冷沉淀可作为纤维蛋白原浓缩物的替代选择以提高血浆纤维蛋白原水平,且纤维蛋白原浓缩物似不增加血栓栓塞等不良结局。

关键数值与推荐

  • 高危出血患者应在体外循环脱机前后用粘弹性床旁检测评估纤维蛋白原活性。
  • Clauss法测定血浆纤维蛋白原水平不再推荐无限制使用。
  • 微血管出血时给予纤维蛋白原浓缩物维持生理水平,不追求超常水平。
  • 可考虑用冷沉淀替代纤维蛋白原浓缩物提高血浆纤维蛋白原水平。

临床怎么用

  • 心脏手术高危出血患者优先采用粘弹性床旁检测指导纤维蛋白原替代。
  • 避免无限制依赖Clauss法测定纤维蛋白原水平。
  • 微血管出血时给予纤维蛋白原浓缩物以维持生理水平而非超常水平。

局限性

  • 现有研究样本量小且患者人群异质性大。
  • 给药时机及输血触发与目标水平定义不一致。
  • 缺乏大规模前瞻性多中心研究证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To date, data regarding the efficacy and safety of administering fibrinogen concentrate in cardiac surgery are limited. Studies are limited by their low sample size and large heterogeneity with regard to the patient population, by the timing of fibrinogen concentrate administration, and by the definition of transfusion trigger and target levels. Assessment of fibrinogen activity using viscoelastic point-of-care testing shortly before or after weaning from cardiopulmonary bypass in patients and procedures with a high risk of bleeding appears to be a rational strategy. In contrast, the use of Clauss fibrinogen test for determination of plasma fibrinogen level can no longer be recommended without restrictions due to its long turnaround time, high inter-assay variability and interference with high heparin levels and fibrin degradation products. Administration of fibrinogen concentrate for maintaining physiological fibrinogen activity in the case of microvascular post-cardiopulmonary bypass bleeding appears to be indicated. The available evidence does not suggest aiming for supranormal levels, however. Use of cryoprecipitate as an alternative to fibrinogen concentrate might be considered to increase plasma fibrinogen levels. Although conclusive evidence is lacking, fibrinogen concentrate does not seem to increase adverse outcomes (i.e., thromboembolic events). Large prospective multi-centre studies are needed to better define the optimal perioperative monitoring tool, transfusion trigger and target levels for fibrinogen replacement in cardiac surgery.

来源:Anaesthesia,查看原文。版权归原作者所有。

引用

  1. Erdoes G, Koster A, Meesters MI, et al. The role of fibrinogen and fibrinogen concentrate in cardiac surgery: an international consensus statement from the Haemostasis and Transfusion Scientific Subcommittee of the European Association of Cardiothoracic Anaesthesiology. Anaesthesia. 2019. PMID: 31531856. doi:10.1111/anae.14842

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。